VCgate - Venture Capital Directory  security and privacy guaranteed
 Home    About Us    Product    Download    Order    Contact    Articles    Resources  
 

 
 
FREE NEWSLETTER SIGNUP
  Please enter your email to receive FREE venture capital and private equity special offers, news, and information!
 
Easy Find Venture Capital  
 Buy now - secure order

 Order as a gift - secure order

 Partner Program 
 
 Tell a friend



A venture capital and private equity directory with more than 4,200 investors worldwide.

First Analysis invests in drug development services company

 

Bio-Kinetic Clinical Applications is a drug development services company that designs and conducts Phase I clinical studies for branded pharmaceutical, biotechnology, and generic drug companies. The company is known for its outstanding reputation for clinical quality, developing study designs, recruiting and screening study participants, and collecting and reporting clinical data.

First Analysis recently participated in a funding round that will help Bio-Kinetic nearly double its capacity, strengthen its services in areas such as data analytics, and add management depth required to implement its growth plan.

The First Analysis investment team was led by Jim Macdonald. We collaborated on this investment with our frequent co-investor, Argentum Group. CapitalSource Finance LLC provided debt financing.

First Analysis is a leading private growth-equity investor. It has one of the longest records (20 years) in private capital investing. It has invested over $590 million, has created over $1.4 billion in fund liquidations, and has over $180 million in active portfolio investments. First Analysis focuses on its three sectors of expertise: outsourced services, information technology, and chemistry-enabled businesses.

First Analysis invests for expansion and growth in small and mid-size companies with established business models, high internal growth rates, and large-market leadership potential. The firm is typically the lead or sole investor in its portfolio companies, investing up to $10 million, and it has a number of established co-investor relationships.

 
 
 
   
   
 
 
 Copyright © 2008 VCgate.com
 Use of this Web site constitutes acceptance of the VCgate Terms and Conditions